Reuters logo
BRIEF-FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A
October 26, 2017 / 1:09 PM / in 24 days

BRIEF-FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A

Oct 26 (Reuters) - BioMarin Pharmaceutical Inc

* FDA grants Breakthrough Therapy Designation for BioMarin’s valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy for hemophilia A

* BioMarin Pharmaceutical Inc - ‍BioMarin expects to initiate enrollment of a global Phase 3 program before end of year​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below